The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain

Xu, L.; Nwosu, Lilian Ngozi; Burston, J.J.; Millns, P.J.; Sagar, Devi Rani; Mapp, Paul I.; Meesawatsom, P.; Li, L.; Bennett, Andrew J.; Walsh, D.A.; Chapman, Victoria

doi:10.1016/j.joca.2016.05.015

All Outputs (3)

Targeting the D-series resolvin receptor system for the treatment of osteoarthritic pain (2016)
Journal Article

Objective: Pain is a major symptom of osteoarthritis (OA); current analgesics either do not offer adequate pain relief or are associated with serious side effects. Herein we have investigated the therapeutic potential of targeting the resolvin recept... Read More about Targeting the D-series resolvin receptor system for the treatment of osteoarthritic pain.

Inhibitory effects of aspirin-triggered resolvin D1 on spinal nociceptive processing in rat pain models (2016)
Journal Article

Background Harnessing the actions of the resolvin pathways has the potential for the treatment of a wide range of conditions associated with overt inflammatory signalling. Aspirin-triggered resolvin D1 (AT-RvD1) has robust analgesic effects in behav... Read More about Inhibitory effects of aspirin-triggered resolvin D1 on spinal nociceptive processing in rat pain models.

The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain (2016)
Journal Article

Objective: Nerve growth factor (NGF) has a pivotal role in peripheral hyperalgesia and inflammation; anti-NGF antibodies attenuate pain responses in inflammatory pain models, and in people with osteoarthritis (OA) or low back pain. The aim of this st... Read More about The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain.